The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs
primary unassisted patency in newly created arteriovenous grafts. This record previously
included information for both the GRAFT and FISTULA trials.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators:
Baystate Medical Center Boston University CAMC Health System Duke University Emory University Maine Medical Center MaineHealth St. Louis University The Cleveland Clinic Tyler Nephrology Associates University of Alabama at Birmingham University of Iowa University of Texas Southwestern Medical Center Vanderbilt University Vanderbilt University Medical Center Vascular Surgery Associates LLC Washington University School of Medicine
Treatments:
Aspirin Aspirin, Dipyridamole Drug Combination Clopidogrel Dipyridamole